RBF Capital’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

RBF Capital’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,637	Closed	-$25K	–	559
2022 Q1	$25K	Hold	4,637	–	–	﹤0.01%	517
2021 Q4	$26K	Hold	4,637	–	–	﹤0.01%	515
2021 Q3	$51K	Hold	4,637	–	–	﹤0.01%	478
2021 Q2	$79K	Hold	4,637	–	–	﹤0.01%	478
2021 Q1	$122K	Hold	4,637	–	–	0.01%	426
2020 Q4	$168K	Hold	4,637	–	–	0.01%	368
2020 Q3	$164K	Hold	4,637	–	–	0.02%	330
2020 Q2	$197K	Buy	+4,637	New	+$313K	0.02%	335

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

RBF Capital's EVFM Position: Q2 2022 in Review

RBF Capital sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 4,637 shares — an estimated $25K sold.

RBF Capital first reported a position in EVFM in Q2 2020 and held it in 8 quarters. The position peaked at $197K in Q2 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

RBF Capital reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
RBF Capital sold 4,637 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $25K.
RBF Capital first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
RBF Capital's Evofem Biosciences, Inc. Common Stock position peaked at $197K in Q2 2020.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on RBF Capital's 13F filing for Q2 2022, filed 15 Aug 2022.